04579nam 2200589Ia 450 991081377640332120200520144314.01-61942-351-0(CKB)2550000001040604(EBL)3017734(SSID)ssj0001047813(PQKBManifestationID)11623052(PQKBTitleCode)TC0001047813(PQKBWorkID)11159081(PQKB)10855794(MiAaPQ)EBC3017734(Au-PeEL)EBL3017734(CaPaEBR)ebr10654705(OCoLC)923653492(EXLCZ)99255000000104060420120130d2012 uy 0engur|n|---|||||txtccrAcute rejection risk factors, management and complications /Takumi Kobayashi, Riku Arai, editors1st ed.Hauppauge, NY Nova Science Publishers, Inc.20121 online resource (211 p.)Immunology and immune system disordersDescription based upon print version of record.1-61942-346-4 Includes bibliographical references and index.""ACUTE REJECTION: RISK FACTORS, MANAGEMENT AND COMPLICATIONS""; ""ACUTE REJECTION: RISK FACTORS, MANAGEMENT AND COMPLICATIONS""; ""Library of Congress Cataloging-in-Publication Data""; ""Contents""; ""Preface""; ""Chapter 1: HLA and Non-HLA Genes Polymorphisms: Susceptibility and Severity in Tunisian Patients with Rheumatoid Arthritis""; ""Abstract""; ""1. Introduction""; ""2. Evaluation of Genetic Predisposition to RA""; ""2.1. Prevalence of RA""; ""2.2. Familial Clustering Studies""; ""2.3. Twins Studies""; ""3. Identification of Candidate Genes""; ""3.1. Linkage Studies""""3.2. Candidate Gene Association Studies""""4. Results of Linkage Studies in RA""; ""5. HLA Association With RA""; ""6. Non HLA Candidate Genes Case-control Studies""; ""6.1. Protein Tyrosine Phosphatase Non-Receptor, Type 22 (PTPN22)""; ""6.2. Tumor Necrosis Factor Receptor Type 2 (TNF-R2)""; ""6.3. Peptidyl Arginine Deiminase 4 (PADI 4)""; ""6.4. Fc γ Receptor IIIa (FcγRIIIa)""; ""6.5. Interleukin 1 Receptor Antagonist (IL-1Ra)""; ""6.6. Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4)""; ""6.7. Apo-1/Fas (CD95)""; ""6.8. Adhesion Molecules""; ""7. Patients and Methods""""7.1. Patients and Controls""""7.2. Methods""; ""7.3. Statistical Methods""; ""8. Results""; ""8.1. HLA Typing""; ""a/ DRB1 Genotyping""; ""b/ DRB1*04 Sub-typing""; ""8.2. PTPN22 Genotyping""; ""8.3. CTLA-4 Genotyping""; ""8.4. Apo-1/Fas Genotyping""; ""8.5. FcγR Genotyping""; ""8.6. Adhesion Molecules Genotyping""; ""8.7. IL1 Family Polymorphisms Genotyping""; ""a/ IL1α (C/T -889)""; ""b/ IL1Ra (Intron 2)""; ""c/ IL1β C/T -511 and C/T +3954""; ""9. Discussion""; ""Conclusion""; ""Acknowledgment""; ""References""""Chapter 2: Mechanisms, Management and Consequences of Acute Cellular and Antibody Mediated Rejection in Solid Organ and Reconstructive Transplantation""""Abstract""; ""1. Acute Rejection""; ""2. Kidney Transplantation""; ""2.1 The Banff Classification""; ""2.2 Acute Antibody-Mediated Rejection in Kidney Transplantation""; ""2.3 Acute T-Cell-Mediated Rejection in Kidney Transplantation""; ""2.3.1. Steps in TCMR � 3 Signals [12]""; ""3. Pancreas Transplantation""; ""3.1 The Banff Classification""; ""3.2 Acute Antibody-Mediated Rejection in Pancreas Transplantation""""3.3 Acute T-Cell-Mediated Rejection in Pancreas Transplantation""""4. Liver Transplantation""; ""4.1 Banff Schema for Grading of Liver Allograft Rejection""; ""4.2 Acute Antibody-Mediated Rejection in Liver Transplantation""; ""4.3 Acute T-Cell-Mediated Rejection in Liver Transplantation""; ""5. Intestinal and Multivisceral Transplantation""; ""5.2 Acute Antibody-Mediated Rejection in Intestinal Transplantation""; ""5.3 Acute T-Cell-Mediated Rejection in Intestinal Transplantation""; ""6. Vascularized Composite Allotransplantation""""6.1 Banff Classification of Skin-Containing Composite Tissue Allografts""Immunology and Immune System DisordersGraft rejectionTransplantation immunologyGraft rejection.Transplantation immunology.MiAaPQMiAaPQMiAaPQBOOK9910813776403321Acute rejection3986038UNINA